Challenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.
Authors
- Óscar Rosas‐Carrasco (ORCID: https://orcid.org/0000-0002-0564-5882)
- Carlos Abud‐Mendoza (ORCID: https://orcid.org/0000-0002-3749-5831)
- María Margarita Contreras-Serratos (ORCID: https://orcid.org/0000-0001-7599-7413)
- Diana Fabiola Flores Díaz (ORCID: https://orcid.org/0000-0001-7147-2329)
- Graciela Castro‐Narro (ORCID: https://orcid.org/0000-0001-7511-5396)
- F. Gomez
- Daniel Kuba (ORCID: https://orcid.org/0000-0002-1939-7971)
- Argelia Lara-Solares (ORCID: https://orcid.org/0000-0002-5292-0920)
- Adriana Guzmán-Holst (ORCID: https://orcid.org/0000-0002-6753-2541)
- Alejandro E. Macías (ORCID: https://orcid.org/0000-0002-6573-4350)
- Álvaro Cabrera-García (ORCID: https://orcid.org/0000-0001-7856-2044)
- Abiel Mascareñas de los Santos (ORCID: https://orcid.org/0000-0002-4057-9526)
- Juan Manuel Calleja-Castillo (ORCID: https://orcid.org/0000-0002-0423-9719)
- José Fernando Barba‐Gómez (ORCID: https://orcid.org/0000-0002-2492-1555)
- José Antonio Mata‐Marín (ORCID: https://orcid.org/0000-0003-1329-7811)
- Javier Nieto Guevara (ORCID: https://orcid.org/0000-0002-3073-2830)
- María Yolanda Cervantes-Apolinar
- Gerardo García (ORCID: https://orcid.org/0000-0003-0399-4103)
- Nolvia Ramos
- Juan Carlos Tinoco (ORCID: https://orcid.org/0000-0003-1594-172X)
- Raúl Ricaño
Institutions
- Universidad de Guanajuato (MX)
- Autonomous University of San Luis Potosí (MX)
- Universidad Iberoamericana (MX)
- Universidad México Contemporáneo (MX)
- Centro Médico Nacional La Raza (MX)
- Secretaría de Salud de Jalisco (MX)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Hospital Médica Sur (MX)
- Centro Medico Nacional Siglo XXI (MX)
- Centro Médico ABC (MX)
- Instituto Nacional de Cancerología (MX)
- University of Monterrey (MX)
Publication Details
- Journal
- Vaccines
- Published
- 2024-12-21
- DOI
- https://doi.org/10.3390/vaccines12121441
- Citations
- 1
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- GlaxoSmithKline